Tag Archives: ADHD

FDA Approves Qelbree (viloxazine) for the Treatment of ADHD

FDA Approves Qelbree (viloxazine) for the Treatment of ADHD ROCKVILLE, Md., April 02, 2021 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) approved Qelbree (viloxazine extended-release capsules) for the treatment of attention-deficit hyperactivity… Read More: FDA Approves Qelbree (viloxazine) for the Treatment of ADHD »

College Students With ADHD May Earn Poor Grades and Drop Out

College is tough for many young people. But it can be even more daunting for those with attention-deficit hyperactivity disorder (ADHD). New findings published in the Journal of Clinical Child & Adolescent Psychology suggest that college students with the disorder are more likely to receive lower grades and drop out of school, reports HealthDay. For… Read More: College Students With ADHD May Earn Poor Grades and Drop… »

FDA Approves Adhansia XR (methylphenidate hydrochloride) Extended-Release Capsules for the Treatment of ADHD

FDA Approves Adhansia XR (methylphenidate hydrochloride) Extended-Release Capsules for the Treatment of ADHD Print this page STAMFORD, Conn.–(BUSINESS WIRE) March 01, 2019 –Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., announced that the U.S. Food and Drug Administration (FDA) approved Adhansia XR (methylphenidate hydrochloride) extended-release capsules CII, a central nervous system (CNS) stimulant, for… Read More: FDA Approves Adhansia XR (methylphenidate hydrochloride) Extended-Release Capsules for the… »